Pipeline

BioInvent develops antibody-based drugs to tackle conditions where there is a significant need for new treatments. We currently have four antibody therapeutics in development in the areas of thrombosis, atherosclerosis and cancer (see below). Please click on a product name for further details of each programme.

01legend02tb40203tb40304bi20405bi505v206key

1 BioInvent is developing TB-402 in collaboration with ThromboGenics. The companies are interested in out-licensing this product for late-stage development and commercialisation.

2 BioInvent and ThromboGenics partnered with Roche for the development of TB-403. Roche will undertake all future development and commercialisation. BioInvent and ThromboGenics retain co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

3 BioInvent partnered with Genentech for the development of BI-204. Under the terms of the agreement, Genentech received the North American rights to the drug, while BioInvent retain the rights for the rest of the world.

BioInvent International • SE-223 70 Lund, Sweden • Visiting: Sölvegatan 41, Lund, Sweden • Tel: +46 (0)46-286 85 50 • E-mail: info@bioinvent.com